ADA: Bempedoic Acid Cuts MACE in Statin-Intolerant Patients
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, June 26, 2023 -- Bempedoic acid is associated with a reduction in major adverse cardiovascular events among statin-intolerant primary prevention patients, according to a study published online June 24 in the Journal of the American Medical Association to coincide with the annual meeting of the American Diabetes Association, held from June 23 to 26 in San Diego.
Steven E. Nissen, M.D., from the Cleveland Clinic, and colleagues conducted a masked, randomized trial involving 13,970 statin-intolerant patients, including 4,206 primary prevention patients to determine the effects of bempedoic acid on cardiovascular outcomes. Participants were randomly assigned to oral bempedoic acid or matching placebo (2,100 and 2,106 patients, respectively).
The researchers found that bempedoic acid reduced low-density lipoprotein cholesterol levels by 30.2 mg/dL and high-sensitivity C-reactive protein levels by 0.56 mg/L compared with placebo (reductions of 21.3 and 21.5 percent, respectively). A significant risk reduction was seen in the primary end point of first occurrence of any component of a composite of cardiovascular death, nonfatal myocardial infarction (MI), nonfatal stroke, or coronary revascularization (111 versus 161 events [5.3 versus 7.6 percent; adjusted hazard ratio, 0.70]) during follow-up for a median of 39.9 months. Significant risk reductions were also seen in key secondary end points, including the composite of cardiovascular death, MI, or stroke; MI; cardiovascular death; and all-cause mortality (hazard ratios, 0.64, 0.61, 0.61, and 0.73, respectively).
"Administration of bempedoic acid in patients unable or unwilling to take guideline recommended doses of a statin was associated with a significant reduction in the primary end point, four-component major adverse cardiovascular events," the authors write.
Several authors disclosed ties to pharmaceutical companies, including Esperion Therapeutics, which manufactures bempedoic acid and funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Read this next
Fish Oil Beneficial for Reducing Risk for Cardiovascular Disease Progression
WEDNESDAY, May 22, 2024 -- The role of regular use of fish oil supplements varies for people with and without cardiovascular disease, according to a study published online May 21...
Ultraprocessed Foods Increase Adiposity, Cardiometabolic Risk in Children
WEDNESDAY, May 22, 2024 -- High ultraprocessed food (UPF) consumption in young children is associated with adiposity and other cardiometabolic risk factors, according to a study...
Physical Activity Time, Step Counts Yield Similar Results
TUESDAY, May 21, 2024 -- Moderate-to-vigorous physical activity (MVPA) time and step counts are similarly associated with all-cause mortality and cardiovascular disease, according...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.